New Risk • Apr 04
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.25.4m market cap, or US$3.91m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). 공시 • Nov 25
Strategic Partners A/S, Annual General Meeting, Apr 28, 2026 Strategic Partners A/S, Annual General Meeting, Apr 28, 2026, at 10:00 Romance Standard Time. 공시 • Sep 17
Strategic Partners A/S Revises Earnings Guidance for the Fiscal Year 2025 Strategic Partners A/S revised earnings guidance for the fiscal year 2025. Based on the first half of the year the company changes its outlook from previously an operating loss in the range of DKK -3 to -4 million to DKK -2 to -3 million. New Risk • Mar 09
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (kr.31.7m market cap, or US$4.61m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (8.8% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). New Risk • Feb 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.32.6m market cap, or US$4.57m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding). 공시 • Jan 10
Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP). Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025. As part of acquisition, 2,327,058 shares were acquired.
Stockslatten AB completed the acquisition of 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025. 공시 • Dec 27
Strategic Partners A/S, Annual General Meeting, Mar 26, 2025 Strategic Partners A/S, Annual General Meeting, Mar 26, 2025. New Risk • Sep 25
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.37.5m market cap, or US$5.62m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding). New Risk • Aug 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Danish stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr.33.9m market cap, or US$5.07m). Board Change • Mar 11
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Jakob Have is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. 공시 • Feb 22
Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI). Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024. Orphazyme informed CombiGene that they in total have acquired approximately 10% of the outstanding shares in CombiGene, which makes Orphazyme one of the larger shareholders in the Company. Orphazyme A/S (CPSE:ORPHA) completed the acquisition of an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024. 공시 • May 18
Orphazyme A/S Announces Board Changes Orphazyme A/S announced that during the Annual General Meeting on May 17, 2023, Bo Jesper Hansen, John Sommer Schmidt and Anders Fink Vadsholt withdrew their candidacy as members of the Board of Directors. Michael Schlomo Gabriely Hove, Jakob Færch Bendtsen and Jakob Alsted Have were elected as new members of the Board of Directors by the general meeting. 공시 • Dec 06
Orphazyme A/S to Report First Half, 2023 Results on Sep 12, 2023 Orphazyme A/S announced that they will report first half, 2023 results on Sep 12, 2023 Breakeven Date Change • Mar 01
Forecast to breakeven in 2024 The 3 analysts covering Orphazyme expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr.46.7m in 2024. Average annual earnings growth of 58% is required to achieve expected profit on schedule. Breakeven Date Change • Jan 01
Forecast to breakeven in 2024 The 4 analysts covering Orphazyme expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr.187.8m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule. Price Target Changed • Sep 01
Price target decreased to kr.81.00 Down from kr.111, the current price target is an average from 6 analysts. New target price is 146% above last closing price of kr.32.98. Stock is down 63% over the past year. Executive Departure • Jul 06
Independent Director Martijn Kleijwegt has left the company On the 30th of June, Martijn Kleijwegt's tenure as Independent Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Martijn's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years. Executive Departure • Jul 06
Independent Director Remi P. Droller has left the company On the 30th of June, Remi P. Droller's tenure as Independent Director ended after 6.5 years in the role. We don't have any record of a personal shareholding under Remi P.'s name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years. Executive Departure • Jul 06
Independent Director Anders Hedegaard has left the company On the 30th of June, Anders Hedegaard's tenure as Independent Director ended after 3.6 years in the role. As of March 2021, Anders still personally held 15.68k shares (kr.1.5m worth at the time). A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years. Major Estimate Revision • Jun 20
Consensus revenue estimates fall to kr.95.0m The consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from kr.205.5m to kr.95.0m. Forecast losses increased from -kr.7.71 to -kr.9.01 per share. Biotechs industry in Denmark expected to see average net income growth of 0.07% next year. Consensus price target up from kr.111 to kr.127. Share price fell 30% to kr.56.00 over the past week. Price Target Changed • Jun 20
Price target increased to kr.127 Up from kr.111, the current price target is an average from 3 analysts. New target price is 126% above last closing price of kr.56.00. Stock is down 42% over the past year. Executive Departure • Mar 27
Independent Director has left the company On the 25th of March, Sten Verland's tenure as Independent Director ended after 10.3 years in the role. We don't have any record of a personal shareholding under Sten's name. A total of 2 executives have left over the last 12 months. Price Target Changed • Feb 25
Price target lowered to kr.135 Down from kr.154, the current price target is an average from 6 analysts. The new target price is 82% above the current share price of kr.74.00. As of last close, the stock is down 25% over the past year. Is New 90 Day High Low • Jan 14
New 90-day high: kr.78.30 The company is up 13% from its price of kr.69.20 on 16 October 2020. The Danish market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 10.0% over the same period. Is New 90 Day High Low • Dec 12
New 90-day low: kr.56.30 The company is down 32% from its price of kr.82.50 on 11 September 2020. The Danish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Oct 21
New 90-day low: kr.66.00 The company is down 37% from its price of kr.104 on 22 July 2020. The Danish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Sep 22
New 90-day low: kr.80.60 The company is down 14% from its price of kr.94.00 on 24 June 2020. The Danish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.